Fabry's Disease

Also known as: Fabry's disease / Fabry Disease / Angiokeratoma corporis diffusum universale / Fabry (-Anderson) disease / Lipidoses / Alpha galactosidase A deficiency

DrugDrug NameDrug Description
DB00103Agalsidase betaRecombinant human alpha-galactosidase A. The mature protein is composed of 2 subunits of 398 residues. Protein is glycosylated and produced by CHO cells
DB05018MigalastatFabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A) [FDA Label, F1107, L4274, L4263]. This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other organs [FDA Label, F1107, L4274, L4278]. In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and an estimated more than 50 percent of these diagnosed patients are currently untreated [L4274]. Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who have amenable GLA variants [FDA Label, F1107, L4274, L4278]. In these patients, migalastat works by stabilizing the body’s own dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate [FDA Label, F1107, L4274, L4278]. Globally, it is estimated that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants that are treatable with migalastat [L4274]. Given the rarity of Fabry disease and the proportion of Fabry disease patients that could benefit from migalastat therapy, Amicus Therapeutics' brand name Galafold was approved using the Accelerated Approval pathway, under which the FDA may approve drugs for serious conditions where there is an unmet medical need and where a drug is shown to have certain effects that are reasonably likely to predict a clinical benefit to patients [FDA Label, F1107, L4274, L4278]. A further study is required to verify and describe the clinical benefits of Galafold, and the sponsor will be conducting a confirmatory clinical trial of Galafold in adults with Fabry disease [FDA Label, F1107, L4274, L4278]. Additionally, Galafold was alzo granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines that the drug, if approved, would provide a significant improvement in treating, diagnosing or preventing a serious condition over available therapies [FDA Label, F1107]. Galafold also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases [FDA Label, F1107]. As of August 2018, migalastat under Amicus Therapeutics' brand name Galafold is currently approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland, and the United States.
DrugDrug NamePhaseStatusCount
DB00173Adenine1Completed1
DB00103Agalsidase beta1Completed2
DB00128Aspartic acid1Completed1
DB14872Lucerastat1Completed1
DB05018Migalastat1Completed3
DB09153Sodium chloride1Completed1
DB12000Apabetalone1 / 2Not Yet Recruiting1
DB14992Pegunigalsidase alfa1 / 2Active Not Recruiting1
DB14992Pegunigalsidase alfa1 / 2Completed2
DB00103Agalsidase beta2Completed9
DB00103Agalsidase beta2Terminated1
DB00996Gabapentin2Withdrawn1
DB05018Migalastat2Completed5
DB05018Migalastat2Terminated1
DB00103Agalsidase beta3Completed5
DB00103Agalsidase beta3Recruiting1
DB14872Lucerastat3Recruiting2
DB05018Migalastat3Active Not Recruiting1
DB05018Migalastat3Completed2
DB05018Migalastat3Recruiting1
DB05018Migalastat3Terminated1
DB14992Pegunigalsidase alfa3Active Not Recruiting1
DB14992Pegunigalsidase alfa3Enrolling by Invitation2
DB14992Pegunigalsidase alfa3Recruiting2
DB14992Pegunigalsidase alfa3Withdrawn1
DB00103Agalsidase beta4Completed7
DB00103Agalsidase beta4Recruiting1
DB00103Agalsidase beta4Withdrawn1
DB00103Agalsidase betaNot AvailableCompleted2
DB00103Agalsidase betaNot AvailableNo Longer Available1
DB00584EnalaprilNot AvailableCompleted1
DB01362IohexolNot AvailableTerminated1
DB05018MigalastatNot AvailableApproved for Marketing1
DB05018MigalastatNot AvailableNot Yet Recruiting1
DB00910ParicalcitolNot AvailableCompleted1
DB00809TropicamideNot AvailableCompleted1